Joshua Richter, MD, has worked as an Associate Professor at the Tisch Cancer Institute at Mount Sinai, New York, NY, since 2018 and is Director of Multiple Myeloma at the Blavatnik Family-Chelsea Medical Center. He began his medical career at New York Medical College, where he obtained his medical degree and stayed on to complete a residency at St Vincent’s Medical Center. Dr Richter trained as a Hematology Oncology fellow at Yale Cancer Center, New Haven, CT.
Prior to his current appointment at Mount Sinai, Dr Richter served as Clinical Assistant Professor at Rutgers University, New Brunswick, NJ, and worked in the division of myeloma at the John Theurer Cancer Center, Hackensack, NJ. He has published extensively on novel therapies and precision medicine in plasma cell dyscrasias and has given national and international talks on his work.
Speaking on developing precision medicine approaches in multiple myeloma
Dr Richter’s extensive research record covers multiple myeloma, light chain amyloidosis, plasma cell leukemia and Waldenstrom’s macroglobulinemia. He has a strong interest in novel immunotherapies -particularly multifunctional antibodies- and early phase clinical trials, which he has had significant involvement in, in the myeloma field. Dr Richter particularly strives to develop precision medicine approaches in myeloma treatment.